Tema GLP-1 Obesity & Cardiometabolic ETF (HRTS)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
HRTS Chart
New Year, New Strategy: Navigating Weight Loss ETFs
With the start of 2026, the annual focus on weight loss resolutions presents a timely opportunity for financial advisors to discuss the investment potential of GLP-1 agonists with their clients. This class of drugs has fundamentally altered the healthcare sector's growth projections.
Tap the Weight-Loss Drug Market With These ETFs
Investors seeking to tap the boom in weight-loss drug treatment could consider these ETFs.
How to capitalize on the weight loss revolution with Tema Obesity & Cardiometabolic ETF (HRTS)
The weight loss revolution sparked by Novo Nordisk last year is attracting many investors towards the high risk biotech sector. An ETF like HRTS gives a lower risk exposure to the sector.
Tema GLP-1 Obesity & Cardiometabolic ETF Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TT Timothy Tenneriello Oliver Lagore Vanvalin Investment Group | 30,841 | $985,139.2 | $1.11M | $125,445.21 | 12.73% |
 Michael Byun SageView Advisory Group LLC | 141 | $4,976 | $5,163.42 | $187.42 | 3.77% |
 Lukas Lindgren Abound Wealth Management | 22 | $760.55 | $791.78 | $31.23 | 4.11% |
 Benj Foor Frazier Financial Advisors, LLC | 1,750 | $59,815 | $63,805 | $3,990 | 6.67% |
 Harbor Asset Planning Inc. Harbor Asset Planning Inc. | 15 | $429 | $547.87 | $118.87 | 27.71% |
Tema GLP-1 Obesity & Cardiometabolic ETF (HRTS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Tema GLP-1 Obesity & Cardiometabolic ETF ever had a stock split?
Tema GLP-1 Obesity & Cardiometabolic ETF Profile
| NASDAQ (NMS) Exchange | US Country |
Overview
The company is focused on investing primarily in publicly listed companies that are significantly involved in the development, production, and marketing of products or services related to GLP-1 and the treatment of cardiovascular and/or metabolic diseases. With a strategic investment criterion that requires at least 80% of its net assets, which includes funds borrowed for investment purposes, to be allocated in this sector, the fund aims to provide investors with exposure to a niche yet critically important area of healthcare. The investment fund is characterized by its narrow focus on companies generating at least half of their revenues from the mentioned healthcare segments, as outlined by the Centers for Disease Control and Prevention's definitions. The portfolio is expected to be composed of a select group of companies, ranging from more than 15 to no more than 100, positioning the fund as non-diversified in its investment approach.
Products and Services
The fund offers a specialized investment product with the following characteristics:
- Specialized Investment Focus: The fund invests in public companies engaged in the GLP-1 sector and the treatment of cardiovascular and metabolic diseases, ensuring that investors have dedicated exposure to these high-potential areas.
- Revenue-based Investment Criteria: Companies included in the fund's portfolio are required to derive at least 50% of their revenues from products or services related to the specified medical conditions, highlighting the fund's targeted approach.
- Portfolio Diversification: While the fund is non-diversified, meaning it invests in a relatively smaller pool of companies, it maintains a balance between more than 15 and no more than 100 different entities. This strategy aims to manage risk while still offering the potential for significant returns from the healthcare sector.
